These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12972136)

  • 1. Glycoprotein IIb/IIIa inhibitor therapy and outcomes after percutaneous coronary intervention.
    Tepper RI; Simonian N
    Am J Cardiol; 2003 Sep; 92(6):771-2. PubMed ID: 12972136
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.
    Bhatt DL; Lincoff AM; Kereiakes DJ; Tcheng JE; Simoons ML; van der Wieken LR; Godfrey N; Califf RM; Topol EJ
    Am J Cardiol; 1998 Nov; 82(9):1105-6, A6. PubMed ID: 9817488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
    Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML
    Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
    Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
    Shimpi RA
    J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
    [No Abstract]   [Full Text] [Related]  

  • 7. The dark side of platelet glycoprotein IIb/IIIa receptor inhibitors during percutaneous coronary interventions.
    Klein LW; Calvin JE
    Am J Cardiol; 2003 May; 91(10):1199-202. PubMed ID: 12745103
    [No Abstract]   [Full Text] [Related]  

  • 8. [Glycoprotein (GP) IIb/IIIa platelet inhibitors in acute ischemic syndrome and percutaneous coronary intervention].
    Caramori PR; Casco JR; Zago AJ; Adelman AG
    Arq Bras Cardiol; 1998 Nov; 71(5):725-34. PubMed ID: 10347959
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
    Cho L; Chew DP; Moliterno DJ; Roffi M; Ellis SG; Franco I; Bajzer C; Bhatt DL; Dorosti K; Simpfendorder C; Tuzcu M; Yadav JS; Brener S; Raymond R; Whitlow P; Topol EJ; Lincoff AM
    Am J Cardiol; 2003 Mar; 91(6):742-3. PubMed ID: 12633814
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
    Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
    Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age.
    Iakovou I; Dangas G; Mehran R; Mintz GS; Lansky AJ; Aymong ED; Nikolsky E; Vagaonescu T; Glasser LA; Stone GW; Leon MB; Moses JW
    Am J Cardiol; 2003 Nov; 92(9):1083-6. PubMed ID: 14583360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa inhibitors: do they still have a role?
    Bhatt DL
    J Am Coll Cardiol; 2011 Mar; 57(10):1200-1. PubMed ID: 21371636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.